Related Experiment Video

Updated: Jul 10, 2026

Preparation of Primary Acute Lymphoblastic Leukemia Cells in Different Cell Cycle Phases by Centrifugal Elutriation
09:09

Preparation of Primary Acute Lymphoblastic Leukemia Cells in Different Cell Cycle Phases by Centrifugal Elutriation

Published on: November 10, 2017

Amplification at 7q22 targets cyclin-dependent kinase 6 in T-cell lymphoma

S Nagel1, E Leich, H Quentmeier

  • 1Department of Human and Animal Cell Cultures, DSMZ, Braunschweig, Germany. sna@dsmz.de

Leukemia
|November 9, 2007
PubMed

Insights

Genomic amplification of CDK6 in T-cell lymphoma drives cell proliferation. This finding identifies CDK6 as a potential therapeutic target for T-cell lymphomas, offering new avenues for rational treatment strategies.

Area of Science:

  • Oncology
  • Genetics
  • Molecular Biology

Background:

  • Recurrent chromosomal aberrations are key drivers in hematopoietic tumors.
  • Identifying and functionally characterizing these aberrations is crucial for developing targeted therapies.

Purpose of the Study:

  • To investigate the genomic amplification at 7q22 in anaplastic large-cell lymphoma (ALCL) cell line SU-DHL-1.
  • To identify and functionally characterize the target genes within this amplified region, specifically focusing on their role in T-cell lymphoma pathogenesis.

Main Methods:

  • Cytogenetic analysis to map the amplicon region.
  • Copy-number determination to quantify amplification levels.
  • Gene expression analysis to identify potential targets.
  • Cellular assays (growth, cell cycle) to assess functional impact.
  • Analysis of primary T-cell lymphoma samples for amplification frequency.

Main Results:

  • A 5- to 6-fold genomic amplification at 7q22 was identified in SU-DHL-1 cells.
  • Cyclin-dependent kinase 6 (CDK6) was identified as a highly expressed gene within the amplified region.
  • SU-DHL-1 cells showed reduced sensitivity to rapamycin, consistent with CDK6 overexpression.
  • CDK6 locus amplification was found in 23% of peripheral T-cell lymphomas not otherwise specified, but rarely in ALCL (1%).

Conclusions:

  • The 7q22 amplicon targets CDK6, a critical cell cycle regulator in T-cell lymphomas.
  • CDK6 overexpression confers a proliferative advantage and impacts drug sensitivity.
  • CDK6 represents a novel and promising therapeutic target for T-cell lymphomas.

More Related Videos

Identification of Quiescent Cells in a Zebrafish T-Cell Acute Lymphoblastic Leukemia Model Using Cell Proliferation Staining06:41

Identification of Quiescent Cells in a Zebrafish T-Cell Acute Lymphoblastic Leukemia Model Using Cell Proliferation Staining

Published on: July 19, 2024

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

Related Concept Videos

M-Cdk Drives Transition Into Mitosis02:15

M-Cdk Drives Transition Into Mitosis

Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
Anaphase Promoting Complex00:50

Anaphase Promoting Complex

The stepwise destruction of specific proteins is necessary for the progression and completion of the cell cycle. Such proteins are ubiquitinated by ubiquitin ligases and then subsequently destroyed by the proteasome. The SCF (Skp1/Cullin/F-box) and the anaphase-promoting complex (APC) are two important ubiquitin ligases involved in cell cycle progression. While SCF is active throughout the cell cycle, APC gets activated during metaphase to anaphase transition. Cdc20 or Cdh1 binds to APC and...
Positive Regulator Molecules02:39

Positive Regulator Molecules

Mitotic cell division results in daughter cells that exactly resemble the parent cell. However, errors in the DNA replication or distribution of genetic material may lead to genetic mutations that may be passed down to every new cell formed from the resulting abnormal cell. Propagation of such mutant cells is restricted through checkpoint mechanisms present at different stages of the cell cycle. These checkpoints involve regulator molecules that either promote or demote cell cycle events.
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...